A multicenter clinical trial is designed to evaluate the efficacy of newly formulated lipid-lowering regimens in patients with familial hypercholesterolemia. The study randomizes 360 patients equally into 6 distinct treatment arms: high-intensity statin monotherapy, statin plus ezetimibe, statin plus a PCSK9 inhibitor, statin plus bempedoic acid, PCSK9 inhibitor monotherapy, and a placebo group.
After 12 weeks, an initial one-way analysis of variance (ANOVA) reveals a statistically significant difference in the mean percentage reduction of LDL cholesterol across the groups (). The investigators plan to conduct post-hoc pairwise comparisons using independent -tests to identify which specific groups differ from one another. To control the family-wise Type I error rate at , they apply a Bonferroni correction by dividing the overall by the total number of unique pairwise comparisons.
How many unique pairwise comparisons can be made among the treatment arms in this study?
Cevap: 15 comparisons